NATERA INC (NTRA) Stock News

Natera to Present New Data at the 2025 ASCO GI Symposium

Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone

The company is working to expand the uses and reimbursement for its blood-based tests for cancer.

Looking Into Natera's Recent Short Interest

Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?

Eleven large-cap stocks were the worst performers in the last week. Short positions announced for FTAI, revenue updates for MRNA, and price forecasts changed for GME, SNAP, RKLB, NTRA, LLY, ICLR, BNTX, NVO, and BMRN.

Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year

Natera Announces Innovation Roadmap, with Advancements in MRD and Early Cancer Detection

Interesting NTRA Put And Call Options For December 19th

Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024

Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings

Natera to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Why NASDAQ:NTRA qualifies as a high growth stock.

Should you consider NATERA INC (NASDAQ:NTRA) for high growth investing?

Stocks Mostly Down Pre-Bell Ahead of Holiday-Shortened Trading Week; Asia, Europe Up

The benchmark US stock measures were mostly trending lower before the opening bell Monday, as trader

Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings

Court Grants Natera’s Request to Include Additional Patent in its Lawsuit Against NeoGenomics

Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer

Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment

Natera Larger Than S&P 500 Component Teledyne Technologies

Clinical Validation Study on Natera’s Fetal RhD NIPT Published in Obstetrics & Gynecology

Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients

Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium

Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal™

/PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH) ("Guardant Health"), a leading precision oncology company, today announced that a jury in the U.S. District...

Natera Issues Statement on Guardant Health Litigation

Natera Co-Founder and Executive Chairman Matthew Rabinowitz Named 2024 R&D Leader of the Year

Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM

Natera Reports Third Quarter 2024 Financial Results